WFDC2 and ovarian carcinoma: Parallel analyses of HE4 and CA125 in the blood showed a statistically significant increase in the level of the marker in ovarian cancer compared with benign ovarian diseases (Figure 5B), and at advanced stages of ovarian cancer (Figure 5D).